Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Recruiting 1Completed 1Approved for marketing 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 36Lymphoma, Large B-Cell, Diffuse 16Lymphoma 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Burkitt Lymphoma 7Neoplasms 6Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Lymphoma, Follicular 6Leukemia 6Lymphoma, B-Cell 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Recurrence 3Neoplasm Metastasis 3Lymphoma, T-Cell 3Lymphoma, B-Cell, Marginal Zone 3Hodgkin Disease 3Waldenstrom Macroglobulinemia 2Pain 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2Lymphatic Diseases 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Neoplasms 2Hematologic Diseases 2Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumours 1Sezary Syndrome 1

Interventions

radium Ra 223 dichloride 2enzalutamide 2darolutamide 1avelumab 1abiraterone 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Metastatic Castration-resistant Prostate Cancer × Prednisone × Clear all
NCT05405439 2023-11-03

To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Terminated
39 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡